Company intelligence / Profile preview
NovaGo Therapeutics
Schlieren, Switzerlandnovagotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
First patient with acute spinal cord injury was enrolled and dosed in Phase 1b clinical trial as of January 7, 2025. The company's therapeutic antibody candidates have shown to enhance nerve repair and functional recovery in preclinical models.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Human antibody therapeutics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Neurimmune
Beyond the preview
Go deeper on NovaGo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NovaGo Therapeutics.